Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

58.51 +0.02 (+0.03%)
Streaming Delayed Price Updated: 3:27 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
44 45 Next >
News headline image
Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell? ↗
Shares hit another skid on Jan. 13 when the company cut its guidance for 2024 and 2025. 
Via Investor's Business Daily
News headline image
GSK To Buy US-Based Stomach Cancer Drug Developer For Over $1 Billion ↗
GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early treatment stages. 
Via Benzinga
News headline image
GSK Enters Agreement to Acquire IDRx, Inc.
From GSK plc and IDRx, Inc.
Via Business Wire
News headline image
Why CureVac (CVAC) Shares Are Volatile ↗
CureVac shares have been volatile over the past week, gaining some 25%. The stock has seen increased trading volume following the U.S.'s first human death from H5N1 bird flu. 
Via Benzinga
News headline image
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies ↗
Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind. 
Via Benzinga
Topics ETFs
News headline image
Pfizer And GSK's RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder ↗
FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, citing increased Guillain-Barré syndrome risk. Study estimates 7-9 excess GBS cases per million doses. 
Via Benzinga
News headline image
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally ↗
The Louisiana Department of Health on Monday reported the first human death in the U.S. related to the H5N1 bird flu virus. The CDC is also reporting high levels of acute respiratory illnesses... 
Via Benzinga
News headline image
GSK's Sinus Disease Drug Secures Approval In China ↗
China approves GSK's Nucala for chronic rhinosinusitis with nasal polyps, adding to its existing uses in asthma and other eosinophilic conditions. 
Via Benzinga
News headline image
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NYSE:ABBV),(NASDAQ:CRDF) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
From FN Media Group LLC
Via GlobeNewswire
News headline image
Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction ↗
Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in Phase 2. Data expected in 2025. 
Via Benzinga
News headline image
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services ↗
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. 
Via Benzinga
News headline image
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
From FN Media Group LLC
Via GlobeNewswire
News headline image
Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy ↗
Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and, possibly, Robert F. Kennedy Jr. at HHS. 
Via Investor's Business Daily
News headline image
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back? ↗
AbbVie has a lofty goal in cancer treatment, and it could come to fruition in 2025. 
Via Investor's Business Daily
News headline image
What's Going On Moderna Stock On Monday? ↗
Moderna faces index removal, stock plunge, vaccine challenges, and lawsuits, while focusing on R&D in oncology and rare diseases for future growth. 
Via Benzinga
Topics Lawsuit
News headline image
Kennedy's Lawyer Urges FDA To Revoke Polio Vaccine Approval, Endangering Millions Of Children ↗
Lawyer files petition against polio vaccine, part of broader anti-vaccine campaign by Robert F. Kennedy Jr. and Aaron Siri, causing concerns for vaccine policies and pharma companies. Trump considering... 
Via Benzinga
Topics Government
News headline image
Bird Flu Spreads To Cats, Possibly Horses As Officials Signal No Plans To Authorize Vaccination ↗
Avian flu continues to spread with cases in cats, horses, and humans. Scientists monitor wildlife infections. Vaccine development may face challenges. 
Via Benzinga
News headline image
United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis ↗
An analysis of NICE-approved drugs from 2000–2020 reveals trade-offs in NHS resource allocation, with high costs leading to a net loss of population health gains. 
Via Benzinga
News headline image
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing ↗
Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027. 
Via Benzinga
News headline image
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex ↗
GSK's Blenrep combo demonstrates significant survival benefits and improved efficacy in relapsed multiple myeloma compared to Darzalex combo. 
Via Benzinga
News headline image
Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
From GSK plc
Via Business Wire
News headline image
Oracle, Vertiv And A Health Care Stock On CNBC's 'Final Trades' ↗
On CNBC's "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors said Oracle is going to report a strong quarter. 
Via Benzinga
News headline image
Bird Flu Found In Raw Milk Leads To Recall In California ↗
Bird flu has been detected in a batch of raw milk sold in California and a voluntary recall of the milk has been issued at the request of the state's department of public health. 
Via Benzinga
Topics Product Recall
News headline image
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce ↗
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is cut by 17%. 
Via Benzinga
News headline image
Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines? ↗
According to the Los Angeles Times, the total bird flue case count in the U.S. stands at 54; 31 cases are attributed to the dairy industry. 
Via Benzinga
News headline image
GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients ↗
GSK's phase 3 GLISTEN trial demonstrated linerixibat's potential to treat relentless itch in PBC patients, meeting its primary endpoint. 
Via Benzinga
News headline image
European And US Vaccine Stocks Are Under Pressure - Here's WHy ↗
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts. 
Via Benzinga
News headline image
GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why ↗
GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
44 45 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.